Entrada Therapeutics, Inc. (TRDA)
Nasdaq · Healthcare · Biotechnology
$5.48+1.86%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $213M
- 52-week range
- $5.15 – $16.45
- 52-week change
- −9.12%
- EPS (trailing)
- −$3.96
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $25.4M (−87.94%)
- Net income
- −$144M
- Operating margin
- −621.1%
- Diluted EPS
- −$3.47
- Free cash flow
- −$130M
From the company’s annual report on SEC EDGAR.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 152 employees · entradatx.com